Omecamtiv Mecarbil for Heart Failure Turned Down by FDA
Heart failure patients won't be getting another drug on the market in the form of omecamtiv…
Browsing Tag
Mecarbil
Omecamtiv Mecarbil Not Ready for Prime Time, FDA Advisors Say
Omecamtiv mecarbil received a thumbs-down from FDA advisors who complained of its inadequate…
Cytokinetics Announces Outcome of FDA Advisory Committee Vote On Omecamtiv Mecarbil
PDUFA Target Action Date is February 28, 2023 Cytokinetics to Host Conference Call and Webcast on December 14, 2022 at 8:30 am Eastern Time SOUTH SAN FRANCISCO, Calif., Dec. 13, 2022…
Cytokinetics Announces Date for FDA Advisory Committee Meeting to Review New Drug…
SOUTH SAN FRANCISCO, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has informed the…
Cytokinetics Announces FDA Acceptance of New Drug Application for Omecamtiv Mecarbil…
PDUFA Target Action Date Set for November 30, 2022 FDA is Currently Not Planning to Hold an Advisory Committee Meeting to Discuss the Application SOUTH SAN FRANCISCO, Calif., Feb. 04,…